Cowen and Company’s Sarepta Therapeutics SRPT Stock Holding History

Cowen and Company’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-6,900	Closed	-$30.4K	–	680
2024 Q2	$30.4K	Buy	+6,900	New	+$886K	﹤0.01%	361
2022 Q2	–	Sell	-12,000	Closed	-$170K	–	742
2022 Q1	$170K	Buy	12,000 +8,300	+224%	+$636K	0.02%	245
2021 Q4	$17K	Hold	3,700	–	–	﹤0.01%	551
2021 Q3	$32K	Buy	+3,700	New	+$285K	﹤0.01%	433
2020 Q2	–	Sell	-20,500	Closed	-$615K	–	474
2020 Q1	$615K	Buy	20,500 +300	+1%	+$34.3K	0.14%	112
2019 Q4	$351K	Buy	+20,200	New	+$2.04M	0.03%	152

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Cowen and Company's SRPT Position: Q1 2024 in Review

Cowen and Company sold out of Sarepta Therapeutics (SRPT) in Q1 2024, closing a stake of 17,012 shares — an estimated $1.64M sold.

Cowen and Company first reported a position in SRPT in Q4 2019 and held it in 6 quarters. The position peaked at $1.64M in Q4 2023. 415 funds tracked by Wall St. Rank hold SRPT as of Q1 2024.

Cowen and Company reported no remaining Sarepta Therapeutics position as of Q1 2024 after selling out during the quarter.
Cowen and Company sold 17,012 Sarepta Therapeutics shares in Q1 2024, an estimated $1.64M.
Cowen and Company first reported a position in Sarepta Therapeutics in Q4 2019 and held it in 6 quarters.
Cowen and Company's Sarepta Therapeutics position peaked at $1.64M in Q4 2023.
415 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2024.

Based on Cowen and Company's 13F filing for Q1 2024, filed 3 May 2024.